FI3206692T3 - Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja - Google Patents

Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja Download PDF

Info

Publication number
FI3206692T3
FI3206692T3 FIEP15851238.4T FI15851238T FI3206692T3 FI 3206692 T3 FI3206692 T3 FI 3206692T3 FI 15851238 T FI15851238 T FI 15851238T FI 3206692 T3 FI3206692 T3 FI 3206692T3
Authority
FI
Finland
Prior art keywords
compound
use according
liver disease
fatty liver
alcohol
Prior art date
Application number
FIEP15851238.4T
Other languages
English (en)
Finnish (fi)
Inventor
Joseph K Belanoff
Hazel Hunt
Onno C Meijer
Den Heuvel Jose Van
Original Assignee
Corcept Therapeutics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Corcept Therapeutics Inc filed Critical Corcept Therapeutics Inc
Application granted granted Critical
Publication of FI3206692T3 publication Critical patent/FI3206692T3/fi

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/513—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim having oxo groups directly attached to the heterocyclic ring, e.g. cytosine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/56—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids
    • A61K31/57—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone
    • A61K31/573—Compounds containing cyclopenta[a]hydrophenanthrene ring systems; Derivatives thereof, e.g. steroids substituted in position 17 beta by a chain of two carbon atoms, e.g. pregnane or progesterone substituted in position 21, e.g. cortisone, dexamethasone, prednisone or aldosterone
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
FIEP15851238.4T 2014-10-15 2015-10-14 Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja FI3206692T3 (fi)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201462064358P 2014-10-15 2014-10-15
US201462092041P 2014-12-15 2014-12-15
PCT/US2015/055487 WO2016061195A1 (en) 2014-10-15 2015-10-14 Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Publications (1)

Publication Number Publication Date
FI3206692T3 true FI3206692T3 (fi) 2024-05-06

Family

ID=55747256

Family Applications (1)

Application Number Title Priority Date Filing Date
FIEP15851238.4T FI3206692T3 (fi) 2014-10-15 2015-10-14 Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja

Country Status (22)

Country Link
US (5) US10238659B2 (OSRAM)
EP (2) EP4353310A3 (OSRAM)
JP (1) JP6761410B2 (OSRAM)
KR (1) KR102435956B1 (OSRAM)
CN (2) CN111557942B (OSRAM)
AU (1) AU2015333645B2 (OSRAM)
BR (1) BR112017007860B1 (OSRAM)
CA (1) CA2964625C (OSRAM)
DK (1) DK3206692T3 (OSRAM)
ES (1) ES2978871T3 (OSRAM)
FI (1) FI3206692T3 (OSRAM)
IL (1) IL251729B (OSRAM)
MX (1) MX2017004943A (OSRAM)
NZ (1) NZ731060A (OSRAM)
PH (1) PH12017500710B1 (OSRAM)
PL (1) PL3206692T3 (OSRAM)
PT (1) PT3206692T (OSRAM)
RU (1) RU2718921C2 (OSRAM)
SG (1) SG11201703024VA (OSRAM)
UA (1) UA123537C2 (OSRAM)
WO (1) WO2016061195A1 (OSRAM)
ZA (1) ZA201702813B (OSRAM)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists
SG11202011948SA (en) * 2018-06-04 2020-12-30 Corcept Therapeutics Inc Pyrimidine cyclohexenyl glucocorticoid receptor modulators
AU2020239920A1 (en) 2019-03-18 2021-11-04 Arnold L. Newman Method of improving insulin sensitivity
US11548856B2 (en) * 2020-05-06 2023-01-10 Corcept Therapeutics Incorporated Polymorphs of pyrimidine cyclohexyl glucocorticoid receptor modulators
US12144812B2 (en) * 2020-05-06 2024-11-19 Corcept Therapeutics Incorporated Formulations of pyrimidine cyclohexyl glucocorticoid receptor modulators
KR102481705B1 (ko) * 2020-08-04 2022-12-27 연세대학교 산학협력단 트리아졸 유도체를 유효성분으로 포함하는 간 섬유증의 예방 또는 치료용 조성물
WO2022140293A1 (en) * 2020-12-21 2022-06-30 Corcept Therapeutics Incorporated Method of preparing pyrimidine cyclohexyl glucocorticoid receptor modulators
WO2022235647A1 (en) * 2021-05-05 2022-11-10 Corcept Therapeutics Incorporated Methods for reducing liver fat and for treating fatty liver disorders
WO2025174745A1 (en) * 2024-02-12 2025-08-21 Corcept Therapeutics Incorporated MIRICORILANT TREATMENT FOR FATTY LIVER DISEASES and its EFFECTS on LIVER FAT CONTENT, FATTY ACIDS, ACYLGLYCEROLS, and SECONDARY BILE ACIDS
WO2025255357A1 (en) * 2024-06-06 2025-12-11 Corcept Therapeutics Incorporated Methods for preparing and maintaining livers and portions thereof for liver transplantation

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2153546A (en) 1936-07-29 1939-04-11 Universal Draft Gear Attachmen Hand brake actuating mechanism
US4391904A (en) 1979-12-26 1983-07-05 Syva Company Test strip kits in immunoassays and compositions therein
GB0213745D0 (en) * 2002-06-14 2002-07-24 Univ Edinburgh Enzyme
AU2003251970A1 (en) 2002-07-18 2004-02-09 Bristol-Myers Squibb Company Modulators of the glucocorticoid receptor and method
ATE463479T1 (de) 2005-05-18 2010-04-15 Merck Sharp & Dohme D-homoandrosta-17-yl-carbamat-derivate als selektive glucocorticoid-rezeptor-liganden
US8389472B2 (en) * 2005-08-19 2013-03-05 Amylin Pharmaceuticals, Llc Exendin-4 to treat nonalcoholic steatohepatitis and nonalcoholic fatty liver disease
WO2007035759A1 (en) * 2005-09-19 2007-03-29 Johnson & Johnson Pharmaceutical Research & Development L.L.C. Modulation of glucocorticoid receptor expression
GB0601092D0 (en) * 2006-01-19 2006-03-01 Daniolabs Ltd The Prevention Of Systemic Side-Effects Of Glucocorticoids
HUE026057T2 (en) 2006-05-09 2016-05-30 Genzyme Corp Procedures for the Treatment of Fatty Liver Disease, which comprises inhibition of glycosphingolipid synthesis
US9623021B2 (en) 2007-01-22 2017-04-18 Gtx, Inc. Nuclear receptor binding agents
PE20090695A1 (es) 2007-04-13 2009-06-27 Schering Corp Derivados de pirimidindiona como agonistas del receptor de acido nicotinico
WO2009155481A1 (en) 2008-06-20 2009-12-23 Gtx, Inc. Metabolites of selective androgen receptor modulators and methods of use thereof
EA022924B1 (ru) 2009-04-03 2016-03-31 Ф.Хоффманн-Ля Рош Аг ТВЁРДАЯ ФОРМА {3-[5-(4-ХЛОРФЕНИЛ)-1Н-ПИРРОЛО[2,3-b]ПИРИДИН-3-КАРБОНИЛ]-2,4-ДИФТОРФЕНИЛ}АМИДА ПРОПАН-1-СУЛЬФОНОВОЙ КИСЛОТЫ И ЕЁ ПРИМЕНЕНИЕ
CN103596431B (zh) 2011-03-18 2016-06-22 科赛普特治疗公司 嘧啶环己基糖皮质激素受体调节剂
PH12017500710B1 (en) 2014-10-15 2024-01-17 Corcept Therapeutics Inc Fatty liver disease treatment using glucocorticoid and mineralocorticoid receptor antagonists

Also Published As

Publication number Publication date
US12226417B2 (en) 2025-02-18
AU2015333645B2 (en) 2020-01-30
PL3206692T3 (pl) 2024-07-22
AU2015333645A1 (en) 2017-05-04
BR112017007860A2 (pt) 2018-01-16
US20210085682A1 (en) 2021-03-25
EP3206692A4 (en) 2018-05-30
US20160106749A1 (en) 2016-04-21
NZ731060A (en) 2023-07-28
CA2964625C (en) 2023-03-07
PT3206692T (pt) 2024-04-30
CN107106562A (zh) 2017-08-29
JP2017531013A (ja) 2017-10-19
CN111557942A (zh) 2020-08-21
RU2017114596A (ru) 2018-11-15
US10881660B2 (en) 2021-01-05
US20250221995A1 (en) 2025-07-10
CN111557942B (zh) 2023-10-03
SG11201703024VA (en) 2017-05-30
EP3206692A1 (en) 2017-08-23
EP4353310A2 (en) 2024-04-17
EP3206692B1 (en) 2024-04-03
JP6761410B2 (ja) 2020-09-23
DK3206692T3 (da) 2024-04-29
US11590135B2 (en) 2023-02-28
PH12017500710B1 (en) 2024-01-17
MX2017004943A (es) 2017-07-19
CN107106562B (zh) 2020-08-18
PH12017500710A1 (en) 2017-10-09
KR20170066646A (ko) 2017-06-14
ZA201702813B (en) 2019-05-29
RU2017114596A3 (OSRAM) 2019-05-08
UA123537C2 (uk) 2021-04-21
US20230218621A1 (en) 2023-07-13
CA2964625A1 (en) 2016-04-21
RU2718921C2 (ru) 2020-04-15
IL251729B (en) 2020-03-31
US10238659B2 (en) 2019-03-26
US20190151318A1 (en) 2019-05-23
ES2978871T3 (es) 2024-09-23
IL251729A0 (en) 2017-06-29
EP4353310A3 (en) 2024-06-19
WO2016061195A1 (en) 2016-04-21
BR112017007860B1 (pt) 2023-03-07
KR102435956B1 (ko) 2022-08-23

Similar Documents

Publication Publication Date Title
FI3206692T3 (fi) Rasvamaksataudin hoito käyttäen glukokortikoidi- ja mineralokortikoidireseptorien antagonisteja
PH12016502168B1 (en) Imidazo[4,5-c]quinolin-2-one compounds and their use in treating cancer
ME02382B (me) 2-(2,4,5-supstituisani-anilino) piramidisnki derivati kao egfr modulatori korisni za tretman raka
BR112015015477A2 (pt) derivados de 2,3-di-hidro-isoindol-1-ona e métodos de uso dos mesmos como inibidores de btk
CL2015000578A1 (es) Compuesto n-(2-(6-fluoro-1-h-indol-3-il)etil)-3-(2,2,3,3-tetrafluoropropoxi)bencilamina o su sal, antagonista del receptor 5-ht6; composicion farmaceutica; uso en el tratamiento de la enfermedad de alzheimer.
EA201790246A1 (ru) Гетероциклические карбоновые кислоты в качестве активаторов растворимой гуанилатциклазы
FR2997845B1 (fr) Procede de lissage des cheveux a partir d'une composition contenant de l'acide glyoxylique et/ou un de ses derives
HRP20220683T1 (hr) Liječenje parkinsonove bolesti
MX380619B (es) Derivados de glutarimida, uso de los mismos, composicion farmaceutica basada en los mismos y metodos para producir derivados de glutarimida.
PH12016500885A1 (en) Novel heterocyclic compounds
EA201300436A1 (ru) Совместные кристаллы и соли ингибиторов ccr3
JO3279B1 (ar) مشتقات 2-((4- امينو -3- (3- فلورو-5- هيدروكسي فينيل)-h1- بيرازولو [d-3,4] بيرمدين-1-يل )ميثيل )- 3- (2- تراي فلورو ميثيل ) بينزيل ) كوينازولين -4 (h3)- واحد واستخدامها كمثبطات فوسفواينوسيتايد 3- كاينيز
AR067328A1 (es) Formas amorfas estabilizadas de mesilato de imatinib
FR2977486B1 (fr) Compositions cosmetiques sous la forme d'emulsions eau-dans-huile comprenant un derive d'acide jasmonique
EA201990678A1 (ru) Гетероарилкарбоксамидные соединения в качестве ингибиторов ripk2
FR3022462B1 (fr) Composition orale d'anticorps anti-tnfalpha
BR122019016794B8 (pt) derivados de arilamida substituídos por tetrazol, composição farmacêutica que os compreende e seu uso no tratamento de uma condição inflamatória e/ou autoimune
BR112015029504A2 (pt) inibidores quinase
BR112015013414A2 (pt) derivados de naftiridona e seu uso no tratamento, melhora ou prevenção de uma doença viral
EA201390488A1 (ru) Новые агонисты gpr 119
BR112014016450A2 (pt) composto antagonista de leucotrieno b4
MY166057A (en) Carbocyclic nucleosides and their pharmaceutical use and compositions
AR112040A1 (es) Sal de n-(2,6-dietilfenil)-8-({4-[4-(dimetilamino)piperidin-1-il]-2-metoxifenil}amino)-1-metil-4,5-dihidro-1h-pirazolo[4,3-h]quinazolina-3-carboxamida, su preparación, y las formulaciones que la contienen
TH1901004650A (th) สารประกอบเฮเทอโรไซคลิกชนิดใหม่,วิธีการจัดเตรียมสารดังกล่าวและองค์ประกอบเภสัชภัณฑ์ซึ่งประกอบรวมด้วยสิ่งเดียวกันนี้
TH158493A (th) อนุพันธ์ของ 1,2,4-ไตรอะซีน สำหรับการบำบัดของโรคติดเชื้อไวรัส